Physician profile
Robert Guido Michelini
NPI 1366435232
$27,207.60
in general payments reported to CMS, 2019-2025
65 companies · $3,584 in 2025
The $3,584 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,919 · 2020: $3,193 · 2021: $4,167 · 2022: $4,541 · 2023: $4,267 · 2024: $3,537 · 2025: $3,584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $44.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,343.84 |
| Education | $44.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $4,024.04 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $3,030.53 | 2019-2025 | |
| Glaxosmithkline, LLC. | $2,571.14 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals Lp | $1,888.87 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,878.74 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Lilly USA, LLC | $1,654.31 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $1,498.76 | 2019-2025 | |
| Amgen INC. | $1,032.58 | 2019-2025 | Repatha, Otezla, Prolia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $880.67 | 2019-2025 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $762.94 | 2019-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Takeda Pharmaceuticals U.S.A., INC. | $696.85 | 2019-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $628.88 | 2019-2025 | Spravato |
| Mylan Specialty L.P. | $479.14 | 2020-2023 | Yupelri |
| Allergan, INC. | $476.85 | 2019-2020 | |
| Tactile Systems Technology INC | $454.02 | 2020-2024 | Flexitouch Plus, Entre Plus |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Michelini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.